IP Library › Granted Patent US 12,747,248
Granted Patent B2
US 12,747,248 · App. 18/122,892 · Granted Sep 29, 2026

Processes for the preparation of substituted spirooxindole derivatives

Inventors: Kaicheng Zhu (Belmont, MA); Tao Wang (Berkeley Heights, NJ); Xin Zhang (Waltham, MA); Xiaowen Peng (Sudbury, MA); Ruichao Shen (Belmont, MA); Jiajun Zhang (Cambridge, MA); Wei Li (Lexington, MA); Hui Cao (Belmont, MA); Xuri Gao (Newtonville, MA); Guoqiang Wang (Belmont, MA); George G. Wu (Waltham, MA); Yat Sun Or (Waltham, MA)
Assignee: Enanta Pharmaceuticals, Inc.
C07D487/10
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 12,747,248
App. No.
18/122,892
Granted
Sep 29, 2026
Kind
B2
Abstract

The present invention relates to processes for preparing a compound of Formula (A): or a pharmaceutically acceptable salt or solvate thereof. Compound of Formula (A) and pharmaceutical compositions are useful as SARS-CoV-2 3CL pro inhibitors.

Claims (108)

1 . A process for producing a compound of Formula (A),

wherein R 1 is selected from the group consisting of hydrogen, Cl, F, optionally substituted methyl, and optionally substituted methoxy; and R 2 is selected from the group consisting of hydrogen, optionally substituted-C 1 -C 6 alkyl, and optionally substituted-C 1 -C 6 alkylaryl,

said process comprising the steps of

a) reacting a compound of Formula (W) with formaldehyde, to produce a compound of Formula (B):

wherein G 1 is methyl, ethyl or phenyl;

b) converting the compound of Formula (B) to a compound of Formula (C):

c) subjecting the compound of Formula (C) to rearrangement to produce a compound of Formula (D-1):

d) converting the compound of Formula (D-1) to a compound (e-1):

e) converting the compound (e-1) to a compound of Formula (F-1):

wherein X is an anion selected from the group consisting of Cl − , Br − , and CF 3 CO 2 − ;

f) reacting the compound of Formula (F-1) with a compound of Formula (K)

wherein PG 1 is selected from the group consisting of -Boc, -Cbz, —C(O) OMe, —C(O)OEt, -Fmoc, -Troc, -Moz, -Pnz, and -Teoc, to produce a compound of Formula (L):

g) converting the compound of Formula (L), optionally in the presence of a suitable acid, to a compound of Formula (M) or a salt thereof:

(J-1) reducing a compound of Formula (G-a) to produce a compound of Formula (G-b):

(J-2) oxidizing the compound of Formula (G-b) to produce a compound of Formula (G):

(J-3) reacting the compound of Formula (G) with a compound of Formula (G-1), in the presence of a base to produce a compound of Formula (H):

wherein R 3 is methyl, ethyl, or benzyl;

(J-4) converting the compound of Formula (H) to a compound of Formula (I) via Hemetsberger indole cyclization:

(J-5) reacting the compound (I) with a base to yield a compound of Formula (J):

h) reacting the compound of Formula (M) or salt thereof with compound of Formula (J)

wherein R 1 is as previously defined; to provide a compound of Formula (N):

i) converting the compound of Formula (N) to the compound of Formula (A):

2 . The process of claim 1 , wherein R 1 is F and R 2 is isobutyl.

3 . The process of claim 2 , wherein G 1 is methyl, X is Cl − and PG 1 is Cbz.

4 . The process of claim 1 , wherein

in step (b), the reaction is conducted in the presence of di-tert-butyl dicarbonate (Boc anhydride) as a Boc protection reagent and triethylamine as a base;

in step (c), the reaction is conducted in the presence of N-bromosuccinimide (NBS), acetic acid, at a temperature about −30° C.;

in step (d), the reaction is conducted in the presence of ammonia in methanol;

in step (e), the reaction is conducted in the presence of hydrogen chloride in ethyl acetate, and Compound (F-1) wherein X is chloride is separated by crystallization in N,N-dimethylformamide (DMF);

in step (f), the reaction is conducted in the presence of n-propanephosphonic acid anhydride (T3P) and N-methylmorpholine;

in step (g), PG 1 is Cbz, and the reaction is conducted in the presence of H 2 as hydrogen source, palladium on carbon as catalyst, and optionally conducted in the presence of p-toluenesulfonic acid; alternatively, in step (g), the reaction is conducted in the presence of hydrogen bromide in acetic acid;

in step (J-1), the reducing agent is sodium borohydride and borane-tetrahydrofuran complex;

in step (J-2), the oxidizing agent is sodium hypochlorite with TEMPO;

in step (J-3), R 3 is ethyl, and the reaction is conducted in the presence of sodium methoxide or sodium ethoxide as a base, and CF 3 CO 2 Et as a sacrificial electrophile;

in step (J-4), the reaction is conducted in a flow chemistry reactor in solvent mixture of xylene and methanol, the volume ratio of xylene to methanol is 5:1 at about 200° C. as reaction temperature and under about 25 minutes as reaction time;

in step (J-5), the reaction is conducted in the presence of sodium hydroxide and followed by treatment with hydrogen chloride;

in step (h), the reaction is conducted in the presence of N-[(dimethylamino)-1H-1,2,3-triazolo[4,5-b]pyridin-1-ylmethylene]-N-methylmethanaminium hexafluorophosphate N-oxide (HATU), and N-methylmorpholine; and

in step (i), the reaction is conducted in the presence of trifluoroacetic anhydride (TFAA), and triethylamine.

5 . A process for producing a compound of Formula (A),

wherein R 1 is selected from the group consisting of hydrogen, Cl, F, optionally substituted methyl, and optionally substituted methoxy; and R 2 is selected from the group consisting of hydrogen, optionally substituted-C 1 -C 6 alkyl, and optionally substituted-C 1 -C 6 alkylaryl,

said process comprising the steps of,

a) reacting a compound of Formula (W), with formaldehyde, to produce a compound of Formula (B):

wherein G 1 is methyl, ethyl or phenyl;

b) converting the compound of Formula (B) to a compound of Formula (C):

c) subjecting the compound of Formula (C) to rearrangement to produce a compound of Formula (D-1):

d) converting the compound of Formula (D-1) to a compound (e-1):

e) converting the compound (e-1) to a compound of Formula (F-1):

wherein X is an anion, selected from the group consisting of Cl − , Br − , and CF 3 CO 2 − ;

f) reacting the compound of Formula (F-1) with a compound of Formula (K):

wherein PG 1 is selected from the group consisting of -Boc, -Cbz, —C(O) OMe, —C(O) OEt, -Fmoc, -Troc, -Moz, -Pnz, and -Teoc, to produce Compound of Formula (L):

g) converting the compound of Formula (L), optionally in the presence of a suitable acid, to a compound of Formula (M) or a salt thereof:

h) reacting the compound of Formula (M) or salt thereof with compound of Formula (J)

wherein R 1 is as previously defined; to provide a compound of Formula (N):

i) converting the compound of Formula (N) to the compound of Formula (A):

6 . The process of claim 5 , wherein R 1 is F and R 2 is isobutyl.

7 . The process of claim 6 , wherein G 1 is methyl, X is Cl − and PG 1 is Cbz.

8 . The process of claim 5 , wherein

In step (b), the reaction is conducted in the presence of di-tert-butyl dicarbonate (Boc anhydride) as a Boc protection reagent and triethylamine as a base;

In step (c), the reaction is conducted in the presence of N-bromosuccinimide (NBS), acetic acid, at a temperature about −30° C.;

In step (d), the reaction is conducted in the presence of ammonia in methanol;

In step (e), the reaction is conducted in the presence of hydrogen chloride in ethyl acetate, and Compound (F-1), wherein X is chloride, is separated by crystallization in N,N-dimethylformamide (DMF);

In step (f), the reaction is conducted in the presence of n-propanephosphonic acid anhydride (T3P) and N-methylmorpholine;

In step (g), PG 1 is Cbz, and the reaction is conducted in the presence of H 2 as hydrogen source, palladium on carbon as catalyst, and optionally conducted in the presence of p-toluenesulfonic acid; alternatively, in step (g), the reaction is conducted in the presence of hydrogen bromide in acetic acid;

In step (h), the reaction is conducted in the presence of N-[(dimethylamino)-1H-1,2,3-triazolo[4,5-b]pyridin-1-ylmethylene]-N-methylmethanaminium hexafluorophosphate N-oxide (HATU) and N-methylmorpholine; and

In step (i), the reaction is conducted in the presence of trifluoroacetic anhydride (TFAA) and triethylamine.

9 . A process for preparing a compound of Formula (A),

wherein R 1 is selected from the group consisting of hydrogen, Cl, F, optionally substituted methyl, and optionally substituted methoxy; and R 2 is selected from the group consisting of hydrogen, optionally substituted —C 1 -C 6 alkyl, and optionally substituted —C 1 -C 6 alkylaryl,

said process comprising the steps of

(a) reacting a compound of Formula (W) with formaldehyde, to produce a compound of Formula (B):

wherein G 1 is C 1 -C 6 -alkyl or aryl;

(b) converting the compound of Formula (B) to a compound of Formula (C):

(c) subjecting the compound of Formula (C) to rearrangement to produce a compound of Formula (D-1):

(d) converting the compound of Formula (D-1) to a compound (e-1):

(e) converting Compound (e-1) to a compound of Formula (F-1):

wherein X is an anion selected from Cl − , Br − , and CF 3 CO 2 − ;

(f) reacting the compound of Formula (F-1) with a compound of Formula (K):

wherein PG 1 is selected from -Boc, -Cbz, —C(O) OMe, —C(O) OEt, -Fmoc, -Troc, -Moz, -Pnz, and -Teoc; to produce a compound of Formula (L):

(g) converting the compound of Formula (L), optionally in the presence of a suitable acid, to a compound of Formula (M) or a salt thereof:

(h) Reacting the compound of Formula (M) or salt thereof with a compound of Formula (J):

wherein R 1 is as previously defined to provide a compound of Formula (N):

(i) converting the compound of Formula (N) to the compound of Formula (A).

10 . The process of claim 9 , wherein R 1 is fluorine and R 2 is isobutyl.

11 . The process of claim 2 , wherein G 1 is methyl, X is Cl − and PG 1 is Cbz.

12 . A process for producing a compound of Formula (A),

wherein R 1 is selected from the group consisting of hydrogen, Cl, F, optionally substituted methyl, and optionally substituted methoxy; and R 2 is selected from the group consisting of hydrogen, optionally substituted-C 1 -C 6 alkyl, and optionally substituted-C 1 -C 6 alkylaryl,

said process comprising the steps of

a) reacting a compound of Formula (W), with formaldehyde, to produce a compound of Formula (B):

wherein G 1 is C 1 -C 6 -alkyl or aryl;

b) converting the compound of Formula (B) to a compound of Formula (C):

c) subjecting the compound of Formula (C) to rearrangement to produce a compound of Formula (D-1):

d) converting the compound of Formula (D-1) to compound (e-1):

e) converting compound (e-1) to a compound of Formula (F-1):

wherein X is an anion, selected from the group consisting of Cl − , Br − , and CF 3 CO 2 − ;

f) reacting the compound of Formula (F-1) with a compound of Formula (K):

wherein PG 1 is selected from the group consisting of -Boc, -Cbz, —C(O) OMe, —C(O) OEt, -Fmoc, -Troc, -Moz, -Pnz, and -Teoc, to produce Compound of Formula (L):

g) converting the compound of Formula (L), optionally in the presence of a suitable acid, to a compound of Formula (M) or a salt thereof:

alternatively, with a suitable acid, converting Compound of Formula (L) to a salt form of Compound of Formula (M);

(J-1) reducing a compound of Formula (G-a) to produce a compound of Formula (G-b):

(J-2) oxidizing the compound of Formula (G-b) to produce a compound of Formula (G):

(J-2a) reacting the compound of Formula (G) with sodium bisulfite to produce a compound of Formula (G-c):

(J-2b) reacting the compound of Formula (G-c) with a base to produce a compound of Formula (G):

(J-3) reacting the compound of Formula (G) with a compound of Formula (G-1), in the presence of a base to produce a compound of Formula (H):

wherein R 3 is methyl, ethyl, or benzyl;

(J-4) converting the compound of Formula (H) to a compound of Formula (I) via Hemetsberger indole cyclization:

(J-5) reacting the compound (I) with a base to yield a compound of Formula (J), or a salt thereof:

h) reacting the compound of Formula (M) or salt thereof with compound of Formula (J) or salt thereof

wherein R 1 is as previously defined; to provide a compound of Formula (N):

i) converting the compound of Formula (N) to the compound of Formula (A).

Assignments (1)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Sep 15, 2023
From: ZHU, KAICHENG; WANG, TAO; ZHANG, XIN; PENG, XIAOWEN; SHEN, RUICHAO; ZHANG, JIAJUN; LI, WEI; CAO, HUI; GAO, XURI; WANG, GUOQIANG; WU, GEORGE G.; OR, YAT SUN
To: ENANTA PHARMACEUTICALS, INC.
Reel/Frame 064915/0001 →
Continuity (2)
Provisional Application 63321244 · Mar 18, 2022
Related Publication 20230295175A1 · Sep 21, 2023
References Cited (155)
US 8222288B2 · Wang et al. · 2012 [cited by applicant]
US 8222425B2 · Britt et al. · 2012 [cited by applicant]
US 8372802B2 · Gai et al. · 2013 [cited by applicant]
US 8546416B2 · Ambarkhane et al. · 2013 [cited by applicant]
US 9290757B2 · Madison · 2016 [cited by applicant]
US 9309284B2 · Chang et al. · 2016 [cited by applicant]
US 9428739B2 · Colt et al. · 2016 [cited by applicant]
US 9447382B2 · Mack · 2016 [cited by applicant]
US 9474759B2 · Chang et al. · 2016 [cited by applicant]
US 9591858B2 · Valles et al. · 2017 [cited by applicant]
US 9828342B2 · Home et al. · 2017 [cited by applicant]
US 9975885B2 · St John et al. · 2018 [cited by applicant]
US 10130701B2 · Bickerton et al. · 2018 [cited by applicant]
US 10590084B2 · Buckman et al. · 2020 [cited by applicant]
US 10959969B1 · Johnson · 2021 [cited by applicant]
US 11013779B2 · Chang et al. · 2021 [cited by applicant]
US 11021513B2 · Schinazi et al. · 2021 [cited by applicant]
US 11033600B2 · Chang et al. · 2021 [cited by applicant]
US 11045546B1 · Kelly et al. · 2021 [cited by applicant]
US 11058763B2 · Zhang et al. · 2021 [cited by applicant]
US 11058779B2 · Lu et al. · 2021 [cited by applicant]
US 11072787B2 · Wu et al. · 2021 [cited by applicant]
US 11124497B1 · Arnold et al. · 2021 [cited by applicant]
US 11174231B1 · Arnold et al. · 2021 [cited by applicant]
US 11207370B2 · Schinazi et al. · 2021 [cited by applicant]
US 11319325B1 · Zhang et al. · 2022 [cited by applicant]
US 11325916B1 · Shen et al. · 2022 [cited by applicant]
US 11339170B1 · Gao et al. · 2022 [cited by applicant]
US 11352363B1 · Wang et al. · 2022 [cited by applicant]
US 11358953B2 · Panarese et al. · 2022 [cited by applicant]
US 11384090B2 · Wang et al. · 2022 [cited by applicant]
US 11858945B2 · Panarese et al. · 2024 [cited by applicant]
US 11912714B2 · Cao et al. · 2024 [cited by applicant]
US 11919910B2 · Wang et al. · 2024 [cited by applicant]
US 20050143320A1 · Yang et al. · 2005 [cited by applicant]
US 20060014821A1 · He et al. · 2006 [cited by applicant]
US 20080125430A1 · Wang et al. · 2008 [cited by applicant]
US 20090137818A1 · Hilgenfeld et al. · 2009 [cited by applicant]
US 20100272681A1 · Farmer et al. · 2010 [cited by applicant]
US 20100317661A1 · Wang et al. · 2010 [cited by applicant]
US 20130072500A1 · Banka et al. · 2013 [cited by applicant]
US 20130072686A1 · Cadieux et al. · 2013 [cited by applicant]
US 20140148494A1 · Wang et al. · 2014 [cited by applicant]
US 20140243341A1 · Chang et al. · 2014 [cited by applicant]
US 20140378680A1 · Wang et al. · 2014 [cited by applicant]
US 20150133368A1 · Chang et al. · 2015 [cited by applicant]
US 20150336928A1 · Fang et al. · 2015 [cited by applicant]
US 20160014821A1 · Toebes · 2016 [cited by applicant]
US 20170044183A1 · Lim et al. · 2017 [cited by applicant]
US 20180099981A1 · Estrada et al. · 2018 [cited by applicant]
US 20190161472A1 · Ombrato et al. · 2019 [cited by applicant]
US 20200230198A1 · Chang et al. · 2020 [cited by applicant]
US 20200354379A1 · Donald · 2020 [cited by examiner]
US 20210355111A1 · Arnold et al. · 2021 [cited by applicant]
US 20220033383A1 · Panarese et al. · 2022 [cited by applicant]
US 20220041652A1 · Panarese et al. · 2022 [cited by applicant]
US 20220048944A1 · Panarese et al. · 2022 [cited by applicant]
US 20220162216A1 · Wang et al. · 2022 [cited by applicant]
US 20220162231A1 · Wang et al. · 2022 [cited by applicant]
US 20220380377A1 · Zhang et al. · 2022 [cited by applicant]
US 20220402926A1 · Zhang et al. · 2022 [cited by applicant]
US 20230103494A1 · Wang et al. · 2023 [cited by applicant]
US 20230115107A1 · Gao et al. · 2023 [cited by applicant]
US 20230122228A1 · Shen et al. · 2023 [cited by applicant]
US 20230151019A1 · Cao et al. · 2023 [cited by applicant]
US 20230159545A1 · Panarese et al. · 2023 [cited by applicant]
US 20230159546A1 · Kass et al. · 2023 [cited by applicant]
US 20230174531A1 · Panarese et al. · 2023 [cited by applicant]
US 20230174542A1 · Panarese et al. · 2023 [cited by applicant]
US 20230203048A1 · Wang et al. · 2023 [cited by applicant]
US 20230295175A1 · Zhu et al. · 2023 [cited by applicant]
US 20230331734A1 · Cao et al. · 2023 [cited by applicant]
US 20240132512A1 · Zhu et al. · 2024 [cited by applicant]
CN 114057624A · 2022 [cited by applicant]
CN 115894504A · 2023 [cited by applicant]
EP 4159211A1 · 2023 [cited by applicant]
EP 4209494A1 · 2023 [cited by applicant]
GB 2595975A · 2021 [cited by applicant]
WO WO9509828A1 · 1995 [cited by examiner]
WO 0059929A1 · 2000 [cited by applicant]
WO 0208244A2 · 2002 [cited by applicant]
WO 2004101742A3 · 2005 [cited by applicant]
WO 2005113580A1 · 2005 [cited by applicant]
WO 2006061714A2 · 2006 [cited by applicant]
WO 2006061714A3 · 2006 [cited by applicant]
WO 2007038138A2 · 2007 [cited by applicant]
WO 2008144507A2 · 2008 [cited by applicant]
WO 2012099454A1 · 2012 [cited by applicant]
WO 2013049382A1 · 2013 [cited by applicant]
WO 2013166319A1 · 2013 [cited by applicant]
WO 2017222935A1 · 2017 [cited by applicant]
WO 2018023054A1 · 2018 [cited by applicant]
WO 2018042343A2 · 2018 [cited by applicant]
WO 2019086141A1 · 2019 [cited by applicant]
WO 2019086142A1 · 2019 [cited by applicant]
WO 2020081636A1 · 2020 [cited by applicant]
WO 2020221826A1 · 2020 [cited by applicant]
WO 2021205296A1 · 2021 [cited by applicant]
WO 2021206876A1 · 2021 [cited by applicant]
WO 2021206877A1 · 2021 [cited by applicant]
WO 2021207409A2 · 2021 [cited by applicant]
WO 2021226546A1 · 2021 [cited by applicant]
WO 2021250648A1 · 2021 [cited by applicant]
WO 2021252491A1 · 2021 [cited by applicant]
WO 2021252644A1 · 2021 [cited by applicant]
WO 2022013684A1 · 2022 [cited by applicant]
WO 2022020242A1 · 2022 [cited by applicant]
WO 2022020711A1 · 2022 [cited by applicant]
WO 2022021841A1 · 2022 [cited by applicant]
WO 2022070048A1 · 2022 [cited by applicant]
WO 2022109363A1 · 2022 [cited by applicant]
WO 2022159644A1 · 2022 [cited by applicant]
WO 2022235605A1 · 2022 [cited by applicant]
WO 2022251615A1 · 2022 [cited by applicant]
WO 2022256434A1 · 2022 [cited by applicant]
WO 2023086350A1 · 2023 [cited by applicant]
WO 2023109926A1 · 2023 [cited by applicant]
WO 2024076680A1 · 2024 [cited by applicant]
PubChem, SID 332063528, Deposited Apr. 10, 2017. [Retrieved on Feb. 21, 2024] online at https://pubchem.ncbi.nlm.nih.gov/substance/332063528. [cited by applicant]
Chen, L. , “Design, Synthesis, Characterization, and Biological Activities of Novel Spirooxindole Analogues Containing Hydantoin, Thiohydantoin, Urea, and Thiourea Moieties”, J. Agric. Food Chem., 68(39), https://doi.or… [cited by applicant]
Owen, D. R, “An oral SARS-CoV-2 Mpro inhibitor clinical candidate for the treatment of COVID-19”, Science, 374(6575), doi: 10.1126/science.abl4784, Dec. 24, 2021, 1586-1593. [cited by applicant]
Panarese, Joseph D. et al., U.S. Appl. No. 18/102,850, filed Jan. 30, 2023. [cited by applicant]
Pubchem, SID 160923150, deposited Mar. 4, 2013. [cited by applicant]
Pubchem, SID 267351747, deposited Dec. 11, 2015. [cited by applicant]
Pubchem, SID 367622864, May 25, 2018. [cited by applicant]
Pubchem, SID 326247498, deposited Jan. 25, 2017. [cited by applicant]
“1-(2-oxospiro[1H-indole-3,3′-pyrrolidine]-1′-yl)-4-pyridin-2-ylbutane-1,4-dione”, Pubchem CID 145894940. Create Date: Feb. 12, 2020. Date Accessed: Jun. 9, 2023, 2 pgs. [cited by applicant]
Anonymous, “Nirmatrelvir”, Cortellis Database, Retrieved from the Internet: URL:https://www.cortellis.com/drugdiscovery/entity/drug/1126756/product?ent=qR5ruNw5&updateHistoryPage=5&orderBy=_score:desc, Nov. 8, 2022, 3 p… [cited by applicant]
Anonymous, “Pfizer Initiates Phase 1 Study of Novel Oral Antiviral Therapeutic Agent Against SARS-CoV-2 Science Products Stories Newsroom About”, Retrieved from the Internet: URL:https://www.pfizer.com/news/press-releas… [cited by applicant]
Bafna, K., et al., “Structural Similarity of SARS-CoV2 Mpro and HCV NS3/4A Proteases Suggests New Approaches for Identifying Existing Drugs Useful as COVID-19 Therapeutics”, , ChemRxiv online at DOI: 10.26434/chem rxiv.… [cited by applicant]
Baker, J. D, et al., “A drug repurposing screen identifies hepatitis C antivirals as inhibitors of the SARS-CoV-2 main 1 protease”, BioRxiv. Preprint. avail at https://doi.org/10.1101/2020.07.10.197889, Jul. 10, 2020. [cited by applicant]
Chia, C.S. Brian, “Novel Coronavirus Main Protease Di- and Tripeptide Inhibitors for Treating COVID-19”, ACS Med. Chem. Lett., 13(9), URL:https://pubs.acs.org/doi/pdf/10.1021/acsmedchemlett.2c00332, Aug. 8, 2022, 1388-1… [cited by applicant]
Chuck, C-P, et al., “Design, synthesis and crystallographic analysis of nitrile-based broad-spectrum peptidomimetic inhibitors for coronavirus 3C-like proteases”, Euro. J. Med. Chem., 59, https://doi.org/10.1016/j.ejmec… [cited by applicant]
Dai, W., et al., “Structure-based design of antiviral drug candidates targeting the SARS-CoV-2 main protease”, Science, 368(6497), DOI: 10.1126/science. abb4489, 1331-1334, 2020. [cited by applicant]
Efremov, I., et al., “Discovery and Optimization of a Novel Spiropyrrolidine Inhibitor of B-Secretase (BACE1) through Fragment-Based Drug Design”, J. Med. Chem., 55, 9069-9088, 2012. [cited by applicant]
Halford, B., “Pfizer unveils its oral SARS-00V-2 inhibitor—The antiviral candidate is the first orally administered compound to enter clinical trials that targets the virus's main protease”, Chem. & Eng. News, online at… [cited by applicant]
Halford, B., “Pfizer's novel COVID-19 antiviral heads to clinical trials—The small molecule targets coronavirus 3CL protease and is active against multiple coronaviruses in cell studies”, Chem. & Eng. News, online at ht… [cited by applicant]
Kelemen, A., et al., “Spiro[pyrrolidine-3,3′-oxindoles] and Their Indoline Analogues as New 5-HT6 Receptor Chemotypes”, Molecules, 22, DOI: 10.3390/molecules22122221, 1-25, 2017. [cited by applicant]
Konno, S., et al., “3CL Protease Inhibitors with an Electrophilic Arylketone Moiety as Anti-SARS-CoV-2 Agents”, J. Medicinal Chemistry, https://doi.org/10.1021/acs.jmedchem.1c00665, pp. 1-14, 2021. [cited by applicant]
Lee., C., et al., “Structural Basis of Inhibition Specificities of 3C and 3C-like Proteases by Zinc-coordinating and Peptidomimetic Compounds”, J. Biological Chem., 284(12), 7646-7655, 2009. [cited by applicant]
Mandadapu, S., et al., “Macrocyclic Inhibitors of 3c and 3C-Like Proteases of Picornavirus, Norovirus, and Coronavirus”, Bioorg. & Med. Chem. Lett., 23, http:lfdx.doi.org/10.1016/j.bmcl.2013.05.021, 3709-3712, 2013. [cited by applicant]
Marti, C., “Novel Approach to Spiro-Pyrrolidine-Oxindoles and its Application to the Synthesis of (+−)-Horsfiline and (−)-Spirotryprostatin”, ETH Library, Doctoral Thesis, https://doi.org/10.3929/ethz-a-004489068, 1-2, … [cited by applicant]
Owen, D., “Oral inhibitors of the 1-12 SARS-CoV-2 main protease for the treatment of COVID-19”, 261ST Am. Chem. Soc. (ACS) Natl Meet, 1 pg, 2021. [cited by applicant]
Thanigaimalai, P., et al., “Design, synthesis, and biological evaluation of novel dipeptide-type SARS-CoV 3CL protease inhibitors: Structure-activity relationship study”, Euro J. Med. Chem., 65, DOI: 10.1016/J.EJMECH.20… [cited by applicant]
Vandyck, K., et al., “Considerations for the discovery and development of 3-chymotrypsin-like cysteine protease inhibitors targeting SARS-CoV-2 infection”, Current Opinion in Virology, 49, DOI: 10.1016/j.coviro.2021.04.… [cited by applicant]
Wang, Y., et al., “Inhibition of Enterovirus 71 Replication by an a-Hydroxy-Nitrile Derivative NK-1.9k”, Antiviral Res., 141, 91-100, 2017. [cited by applicant]
Xu, J., et al., “Green Oxidation of Indoles Using Halide Catalysis”, Nature Communications, 10:4754, https://doi.org/10.1038/s41467-019-12768-4, 1-11, 2019. [cited by applicant]
Yang, S., et al., “Synthesis, Crystal Structure, Structure-Activity Relationships, and Antiviral Activity of a Potent SARS Coronavirus 3CL Protease Inhibitor”, J. Med. Chem., 49, 4971-4980, 2006. [cited by applicant]
Zhai, Y., et al., “Cyanohydrin as an Anchoring Group for Potent and Selective Inhibitors of Enterovirus 71 3C Protease”, J. Med. Chem., 58, 9414-9420, 2015. [cited by applicant]
Zhang, L., et al., “a-Ketoamides as Broad-Spectrum Inhibitors of Coronavirus and Enterovirus Replication: Structue-Based Design, Synthesis, and Activity Assessment”, J. Med. Chem., 63, https://dx.doi.org/10.1021/acs,jme… [cited by applicant]
Zhou, L., et al., “An Overview of Spirooxindole as a Promising Scaffold for Novel Drug Discovery”, Expert Opinion on Drug Discovery, 15(5), 603-625, 2020. [cited by applicant]
Ziarani, G., et al., “Synthesis of Spiro-Fused Heterocyclic Scaffolds Through Multicomponent Reactions Involving Isatin”, ARKIVOC, 2016 (i), http://dx.doi.org/10.3998/ark.5550190.p009.385, 1, 14-16. [cited by applicant]
Hati, S., “Spiro[pyrrolidine-3, 1-7 3′-oxindole] as potent anti-breast cancer compounds: Their design, synthesis, biological evaluation and cellular target identification”, Sci Reports, 6(1), DOI: 10.1038/srep32213, Aug… [cited by applicant]
Pellegrini, “Synthesis of the Oxindole Alkaloid (−)-Horsfiline”, Tetrahedron Asymmetry 5(10), Oct. 1994, 1979-1992. [cited by applicant]
Pellegrini, “Synthesis of the Oxindole Alkaloid (−)-Horsfiline”, Tetrahedron Asymmetry 5(10), Abstract only, Oct. 1994, 1. [cited by applicant]